Amag pharmaceuticals, inc. (AMAG)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenue from Contract with Customer [Abstract]
Revenues:
Revenues

327,751

474,002

495,769

432,487

-

-

-

-

-

-

-

-

Product sales, net

-

-

-

-

341,816

109,998

71,692

58,287

-

-

16,482

751

Service revenues, net

-

-

-

-

24,132

0

-

-

-

-

-

-

License fee, collaboration and other revenues

-

-

-

-

52,328

14,386

9,164

26,475

8,321

6,132

516

959

U.S. Feraheme product sales, net

-

-

-

-

-

-

-

-

52,097

59,339

-

-

Other product sales and royalties

-

-

-

-

-

-

-

616

831

774

-

-

Royalties

-

-

-

-

-

-

-

-

-

-

180

228

Total revenues

-

-

-

-

418,276

124,384

80,856

85,378

61,249

66,245

17,178

1,938

Costs and expenses:
Cost of product sales

107,193

215,892

161,349

96,314

-

-

-

-

-

-

-

-

Cost of product sales

-

-

-

-

78,509

20,306

11,960

14,220

10,531

7,606

1,013

292

Cost of services

-

-

-

-

9,992

0

-

-

-

-

-

-

Research and development expenses

64,853

44,846

75,017

65,561

42,878

24,160

20,564

33,296

58,140

54,462

36,273

31,716

Acquired in-process research and development

74,856

32,500

65,845

0

0

-

-

-

-

-

-

-

Selling, general and administrative expenses

286,600

227,810

178,151

169,468

160,309

72,254

59,167

53,071

68,863

84,939

77,829

49,536

Impairment of assets

232,300

0

319,246

-

-

-

-

-

-

-

-

-

Impairment of Intangible Assets, Finite-lived

-

-

-

15,724

0

0

-

-

-

-

-

-

Acquisition-related costs

-

-

-

-

11,232

9,478

782

-

-

-

-

-

Restructuring expenses

7,420

0

0

341

4,136

2,023

-

2,215

3,508

2,224

-

-

Total costs and expenses

773,258

521,048

799,608

347,408

307,056

128,221

92,473

102,802

141,042

149,231

115,115

81,544

Operating loss

-445,507

-47,046

-303,839

85,079

111,220

-3,837

-11,617

-17,424

-

-

-

-

Other income (expense):
Interest expense

25,709

51,971

68,382

73,153

53,251

14,697

-

-

-

-

-

-

Gain (Loss) on Extinguishment of Debt

0

-35,922

-10,926

0

-10,449

0

-

-

-

-

-

-

Interest and dividend income

4,285

5,328

2,810

3,149

1,512

975

1,051

1,286

1,747

1,741

3,154

9,139

Other income

428

-74

-70

189

-9,188

217

964

-

-

-

-

-

Total other (expense) income

-

-

-

-

-

-13,505

2,015

-

-

-

-

-

Gains (losses) on investments, net

-

-

-

-

-

-

-

-1,466

-193

408

942

-3,024

Fair value adjustment of settlement rights

-

-

-

-

-

-

-

-

-

-788

-778

1,566

Total other expense, net

-20,996

-82,639

-76,568

-69,815

-71,376

-

-

-180

1,554

1,361

3,318

7,681

Loss from continuing operations before income taxes

-466,503

-129,685

-380,407

15,264

39,844

-17,342

-9,602

-17,604

-78,239

-81,625

-94,619

-71,925

Income tax expense (benefit)

-47

39,700

-175,300

13,200

7,065

-153,159

-

-854

-1,170

-472

-1,268

-278

Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent

-466,456

-169,339

-205,153

2,093

-

-

-

-

-

-

-

-

Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax

0

18,873

10,313

-6,209

-

-

-

-

-

-

-

-

Gain on sale of CBR business

0

87,076

0

0

-

-

-

-

-

-

-

-

Income tax expense

0

2,371

4,388

-1,633

-

-

-

-

-

-

-

-

Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent

0

103,578

5,925

-4,576

-

-

-

-

-

-

-

-

Net loss

-466,456

-65,761

-199,228

-2,483

32,779

135,817

-9,602

-16,750

-77,069

-81,153

-93,351

-71,647

Basic and diluted earnings per share:
(Loss) income from continuing operations (in dollars per share)

-

-

-

0.06

-

-

-

-

-

-

-

-

Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share

-

-

-

-0.13

-

-

-

-

-

-

-

-

Total (in dollars per share)

-

-

-

-0.07

1.04

6.06

-0.44

-0.78

-

-

-

-4.22

(Loss) income from continuing operations (in dollars per share)

-

-

-

0.06

-

-

-

-

-

-

-

-

Income (loss) from discontinued operations (in dollars per share)

-

-

-

-0.13

-

-

-

-

-

-

-

-

Total (in dollars per share)

-

-

-

-0.07

0.93

5.45

-0.44

-0.78

-

-

-

-4.22

Loss from continuing operations (in dollars per share)

-13.71

-4.92

-5.88

-

-

-

-

-

-3.64

-3.90

-5.46

-

Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share

0.00

3.01

0.17

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share (in dollars per share)

-13.71

-1.91

-5.71

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Basic

34,030

34,394

34,907

34,346

31,471

22,416

21,703

-

-

-

17,109

16,993

Weighted average shares outstanding used to compute net loss per share (basic and diluted) (in shares)

-

-

-

-

-

-

-

21,392

21,189

20,806

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

-

34,833

35,308

25,225

21,703

21,392

-

-

17,109

16,993

Product Sales
Revenues

311,190

473,852

495,645

432,170

-

-

-

-

-

-

-

-

Collaboration revenue
Revenue from Contract with Customer, Excluding Assessed Tax

16,400

0

0

-

-

-

-

-

-

-

-

-

Other revenues
Revenues

161

150

124

317

-

-

-

-

-

-

-

-